Douglas Carr, Senior Vice President of Finance and Operations at Century Therapeutics, Inc., filed a statement of changes in beneficial ownership on September 15, 2026, reporting the sale of common stock on September 14, 2026, in connection with the vesting of restricted stock units.
Key Highlights
- Reporting person: Douglas Carr, SVP Finance and Operations at Century Therapeutics, Inc.
- Shares sold: 1,658 shares of Common Stock disposed of on September 14, 2026, at a price of $1.93 per share.
- Purpose of sale: According to the filing, the shares sold represent those "required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units" and were "automatic and not at the discretion of the Reporting Person."
- Remaining ownership: Following the transaction, Carr directly beneficially owned 502,907 shares of Common Stock.
- Exchange and ticker: Century Therapeutics, Inc. trades under NASDAQ:IPSC.
Douglas Carr's Share Disposition at Century Therapeutics
Century Therapeutics, Inc. (NASDAQ:IPSC) is a biopharmaceutical company based at 25 N 38th Street, 12th Floor, Philadelphia, Pennsylvania 19104. The filing was submitted by Douglas Carr, who serves as Senior Vice President of Finance and Operations, in his capacity as a Section 16 reporting officer of the company.
According to the filing, Carr disposed of 1,658 shares of Common Stock on September 14, 2026, using transaction code "S," at a per-share price of $1.93. The filing's footnote states that these sales were automatic, executed solely to satisfy tax withholding obligations arising from the vesting of restricted stock units, and were not made at the discretion of the reporting person. Following this disposition, Carr's direct beneficial ownership in Century Therapeutics common stock stood at 502,907 shares, as reported in the filing.
No derivative securities transactions were reported in Table II of the filing. The statement was filed by one reporting person and signed by Douglas Carr on September 15, 2026, the same date it was submitted to the Securities and Exchange Commission.
What Was Disclosed
The filing disclosed a single sale of 1,658 shares of Century Therapeutics Common Stock at $1.93 per share on September 14, 2026, by SVP Douglas Carr, conducted automatically to cover tax obligations tied to RSU vesting, leaving him with direct ownership of 502,907 shares.



Please wait processing your request...